Illumina (ILMN) Projected to Post Earnings on Thursday

Illumina (NASDAQ:ILMN - Get Free Report) is expected to be releasing its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect Illumina to post earnings of $0.94 per share and revenue of $1.03 billion for the quarter.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, analysts expect Illumina to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Illumina Price Performance

Shares of NASDAQ ILMN traded up $1.37 on Friday, hitting $77.88. The company's stock had a trading volume of 1,190,941 shares, compared to its average volume of 2,283,628. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a market capitalization of $12.33 billion, a price-to-earnings ratio of -10.14, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The stock has a 50 day moving average of $80.07 and a 200-day moving average of $115.86.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Royal Bank of Canada cut their price target on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, April 8th. Citigroup reduced their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Barclays cut their price objective on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research report on Thursday, April 10th. Robert W. Baird decreased their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Finally, Guggenheim cut their price target on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $137.55.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.